The Price of Adherence: Qualitative Findings From HIV Positive Individuals Purchasing Fixed-Dose Combination Generic HIV Antiretroviral Therapy in Kampala, Uganda
- 25 April 2006
- journal article
- research article
- Published by Springer Nature in AIDS and Behavior
- Vol. 10 (4) , 437-442
- https://doi.org/10.1007/s10461-006-9080-z
Abstract
Contrary to early expectations, recent studies have shown near-perfect adherence to HIV antiretrovirals in sub-Saharan Africa We conducted qualitative interviews with patients purchasing low-cost, generic antiretroviral therapy to better understand the social dynamics underlying these findings. We found that concerns for family well-being motivate adherence, yet, the financial sacrifices necessary to secure therapy may paradoxically undermine family welfare. We suggest that missed doses may be more due to a failure to access medication rather than a failure to adhere to medications, and that structural rather than behavioral interventions may be most useful to insure optimal treatment response.Keywords
This publication has 10 references indexed in Scilit:
- Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapyInternational Journal of STD & AIDS, 2005
- Multiple Validated Measures of Adherence Indicate High Levels of Adherence to Generic HIV Antiretroviral Therapy in a Resource-Limited SettingJAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
- Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trialThe Lancet, 2004
- Treating AIDS: Dilemmas of unequal access in UgandaSAHARA-J: Journal of Social Aspects of HIV/AIDS, 2004
- Antiretroviral therapy in AfricaBMJ, 2004
- Doubts about DOT: antiretroviral therapy for resource-poor countriesAIDS, 2003
- Adherence is not a barrier to successful antiretroviral therapy in South AfricaAIDS, 2003
- Is average adherence to HIV antiretroviral therapy enough?Journal of General Internal Medicine, 2002
- Preventing antiretroviral anarchy in sub-Saharan AfricaThe Lancet, 2001
- Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy).2001